[go: up one dir, main page]
Wikipedia

Talk:Parexel

Latest comment: 3 days ago by DWwilliams001 in topic Proposed "Acquisition history" updates
Learn more about this page

note

edit
Latest comment: 17 years ago1 comment1 person in discussion

The article focuses on a clinical trial run by PAREXEL International on behalf of TeGenero. This article should focus on the company and reads like bad press, rather than an unbaised description of the company. 82.44.145.95 17:55, 13 January 2007 (UTC)Reply


I removed the last sentence about refusal to engage with victim of botched tests. That was what the tag referred to. There was absolutely no evidence to substantiate these claims which are serious. Can somebody remove the tag

Templates

edit
Latest comment: 16 years ago3 comments3 people in discussion

Hi, I removed the "verify" template because it seems to me that there is enough sources. However, I leave the "neutrality" template because of the importance given to one source (Brian Deer's reportage) and because I agree that this article should not focus only on the tragical trial, which already has an article (TGN1412). Maybe we should just remove this section (after tranfering into the TGN1412 article) and replace it by a short reference, with a link to TGN1412. What do you think? Polletfa 10:57, 9 March 2007 (UTC)Reply

Agree - stupid to focus on this one trial in a company of 6,500 staff conducting studies for over 25 years, leading to the registration of most of the new medicines in the USA, Europe and Japan. The bias towards the ambulance chasers suing the company and delaying payment to the victims is the real scandal here.

Also agree - the whole TGN1412 episode has enough to be its very own article. —Preceding unsigned comment added by 206.191.43.7 (talk) 18:29, 16 October 2007 (UTC)Reply

==

I agree I think the scandal on TGN1412 could make up an article of its own. Its just ridiculous to insert such issue as representative of the company. It should be mentioned shortly when the company is discussed, but then a link better be inserted to the full blown page on the incident. —Preceding unsigned comment added by Ayaluaklilu (talk • contribs) 13:11, 9 May 2008 (UTC)Reply

TGN1412

edit
Latest comment: 9 years ago3 comments2 people in discussion

The section about TGN1412 appears grossly non-neutral, as it doesn't reflect the reliable sources and appears to be consciously written with the intention of placing blame on TeGenero. Hence the pov-section tag. --Dr. Fleischman (talk) 17:47, 18 February 2015 (UTC)Reply

Its a complex issue for several reasons, which include WP:CRIT, which states that
"Generally, criticisms within an article (other than a "Criticism of ..." article) should in total be well under half of the article, even if sourcing supports filling almost every line of the article with criticism. The minimum is that required by neutrality but the maximum should, in a neutral way, leave a majority of the article as not criticism."
This is a $1.7B company with 15K employees. The article discusses the company in a general way for 3 sentences and then launches into a discussion of the TGN1412 trial that is more than half of the article. A considered and balanced discussion of that trial would involve overweighting it even further. I'd suggest simply summarizing in a sentence and hyperlinking to the article about this incident until the article is increased to mor than a stub. Formerly 98 (talk) 14:52, 19 February 2015 (UTC)Reply
Fine with me. I think a few sentences summarizing the TGN1412 controversy could be written in a much more balanced way than the current content. FWIW there was a lot of uncritical content in this article that I blanked yesterday due to it being unsourced and blatantly promotional. I'll bet there are independent sources out there about Parexel that aren't about the TGN1412 controversy. --Dr. Fleischman (talk) 19:24, 19 February 2015 (UTC)Reply

Proposed "Acquisition history" updates

edit
Latest comment: 3 days ago1 comment1 person in discussion

My name is Danaka Williams and I work for Parexel in the Corporate Communications department. The current "Acquisition history" section relies heavily on citations to Parexel itself, is incomplete, and has a few other issues. I'd like to propose replacing it with a table, similar to what is commonly used on other pages[1][2]. Below is the proposed table that includes every acquisition with independent citations available. Pursuant to WP:COI, I'm asking for an impartial editor to consider whether it would be an incremental improvement to replace the bulleted list with the below table.

New acquisitions section
Date Company Business Location Value (USD) Ref(s).
1 1988 Consulting Statisticians Data and statistics firm Boston, MA [1][2][2]
2 1989 Clinical Trial Analysis division of McDonnell Douglas Corporation Biostatistics and analysis [1][2]
3 1990 Barnett Associates Training, education, logistics support, and IT systems Philadelphia, Pennsylvania [2]
4 1991 Arzneimittelforschung GmbH Phase I-IV clinical trials Germany [2]
5 1996 Sitebase Clinical Systems Data entry and management Massachusetts [3]
6 1996 Caspard Consultants Monitoring and analysis France [3]
7 1996 Washington State and Federal Associates Inc. Marketing and sales Washington, USA [3]
8 1996 Lansal Clinical Pharmaceuticals Clinical trials, phase I-IV Tel-Aviv [3]
9 Rescon Inc. Marketing United States [3]
10 Perceptive Systems Inc. Imaging software United States [3]
11 Kemper-Masterson Validation and compliance consulting Boston, MA [3]
12 1998 PPS Europe Ltd Pharmaceutical marketing United Kingdom 2.9 million shares [4]
13 1998 Logos GmbH Regulatory consulting Germany 100,000 shares [4]
14 1998 Mirai BV Contract Research Organization Netherlands 675,000 shares [4]
15 circa 2000 Farmovs Contract Research Organization South Africa [3]
16 circa 2000 CEMAF Clinical research facility France [3]
17 2001 EDYABE Contract research Latin America [5][6]
18 2002 PW Pharma Systems Clinical trial management software United Kingdom $15.4 million [7]
19 2002 Pracon & Health IQ Medical marketing United States [8]
20 2004 3ClinicalResearch AG Phase I and proof-of-concept clinical trials Germany $12 million [9]
21 2004 Integrated Marketing Concepts Call center for recruiting patients, support, market research, and sales United States [10][11]
22 2005 QdotPharma Phase I and II clinical trials South Africa $6 million [12][13]
23 2006 Behavioral and Medical Research + California Clinical Trials Medical Group Phase I-IV clinical trials California, USA $65 million [14]
24 2007 Apex International Clinical Research Co. Ltd. (minority interest) Contract Research Organization Taiwan $50.9 million [15]
25 2008 ClinPhone Clinical trial automation and management technology United Kingdom $177 million [16][17]
26 2013 Heron Group Economics consulting United Kingdom $38.2 million [18]
27 2012 Liquent Medical and research software United States $72 million [19]
28 2014 ATLAS Medical Services Clinical research Turkey [20]
29 2014 ClinIntel Randomization and trial supply management United Kingdom [21][22]
30 2024 Quantum Solutions Pharmacovigilance India [23]
31 2016 ExecuPharm Holding Company Clinical research services United States [24]
32 2017 The Medical Affairs Company Medical marketing firm United States [25]
33 2016 Health Advances Consulting services United States [26]
34 2017 Anolinx Epidemiology and informatics [27]
35 2020 Model Answers Pharmacokinetic modeling and consulting Australia [28]
36 2020 Roam Analytics Natural Language Processing United States [29]

References

  1. ^ a b "Parexel". Hoover's Handbook of Emerging Companies. Hoovers Business Press. 1999. pp. 240–245. ISBN 1-57311-046-9.
  2. ^ a b c d e Mast, J.A. (1993). Ward's Private Company Profiles. Ward's Private Company Profile. Gale Research. pp. 558–560. ISBN 978-0-8103-9140-6. Retrieved November 23, 2024.
  3. ^ a b c d e f g h i "Parexel". International Directory of Company Histories. Vol. 84. St. James Press. 2007.
  4. ^ a b c Bulkeley, William M. (1998-03-03). "Parexel Pays $148 Million For Three European Firms". The Wall Street Journal. p. B12. ISSN 0099-9660. Retrieved 2016-12-25.
  5. ^ "Parexel International acquires Latin American company". Boston Business Journal. July 30, 2001. Retrieved November 17, 2024.
  6. ^ Kopp, Katherine (August 13, 2001). "Parexel rebounds; grows space, force". Triangle Business Journal. Retrieved November 23, 2024.
  7. ^ "Parexel expands trial management offering". R&D Directions. March 2003. p. 22.
  8. ^ "Parexel Acquires Pracon & HealthIQ". Boston Business Journal.
  9. ^ "Improving Margins". R&D Directions. September 2004. p. 62.
  10. ^ Call, Morning (October 8, 2004). "Integrated Market Concepts sold ** Whitehall firm has been acquired by Boston company". The Morning Call. Retrieved November 11, 2024.
  11. ^ "Parexel enhances capabilities". R&D Directions. November 2004. p. 28.
  12. ^ "Parexel acquires S. Africa pharma for $6M". Boston Business Journal. July 21, 2005. Retrieved November 11, 2024.
  13. ^ Fitzsimmons, Lyle (September 2005). "New tagline shows new philosophy". R&D Directions. p. 52.
  14. ^ "Parexel spends $65M on acquisitions". The Pharmaletter. October 22, 2006. Retrieved November 30, 2024.
  15. ^ Plunkett, J.W. (2008). Plunkett's Biotech & Genetics Industry Almanac. Plunkett's Biotech & Genetics Industry Almanac. Plunkett Research, Limited. p. 465. ISBN 978-1-59392-124-8. Retrieved November 11, 2024.
  16. ^ "ClinPhone PLC". Wall Street Journal. June 16, 2008. p. 8.
  17. ^ Barnes, Kirsty (June 15, 2008). "ClinPhone has Parexel purchase in sight". Outsourcing-Pharma.com. Retrieved November 30, 2024.
  18. ^ "Parexel Acquires Heron Group in Up To $38M Deal". GEN - Genetic Engineering and Biotechnology News. May 1, 2013. Retrieved November 12, 2024.
  19. ^ Armstrong, Mike (December 28, 2012). "Horsham's Liquent sold for $72M". Philadelphia Inquirer. p. A.19.
  20. ^ Research, Zacks Equity (July 7, 2014). "PAREXEL Up on Acquisition of Clinical Research Company". Yahoo Finance. Retrieved November 12, 2024.
  21. ^ Liu, Angus (February 14, 2017). "RTSM service on a mobile app? Parexel did it". Fierce Biotech. Retrieved November 16, 2024.
  22. ^ Brennan, Zachary (October 5, 2014). "Parexel acquires RTSM service provider ClinIntel". Outsourcing-Pharma.com. Retrieved November 30, 2024.
  23. ^ "Parexel International to acquire Quantum Solutions". Mint. March 28, 2015.
  24. ^ Keenan, Joseph (September 28, 2016). "Parexel buying functional service provider ExecuPharm for undisclosed amount". Fierce Biotech. Retrieved November 16, 2024.
  25. ^ Adams, Ben (February 2, 2017). "Parexel in Medical Affairs Company buyout deal, lowers forecast". Fierce Biotech. Retrieved November 16, 2024.
  26. ^ "PAREXEL Announces Execution of Definitive Agreement to Acquire Health Advances". Fierce Biotech. January 21, 2016. Retrieved December 17, 2024.
  27. ^ "SHOWCASE: Outsourcing". PharmaVoice. February 1, 2019. Retrieved November 16, 2024.
  28. ^ "Parexel Acquires Model Answers". Contract Pharma. February 21, 2020. Retrieved November 16, 2024.
  29. ^ "Parexel Acquires Roam Analytics' NLP Capability". Contract Pharma. September 23, 2020. Retrieved November 16, 2024.

DWwilliams001 (talk) 17:36, 17 December 2024 (UTC)Reply

Add topic
Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Parexel&oldid=1263612310"